Conversely, immune-cold tumors such as medulloblastoma and ATRT may require alternative approaches, such as epigenetic modulators to restore MHC expression or HLA-independent adoptive cellular therapies (e.g., CAR-T or NK cell-based treatments) that circumvent classical antigen presentation barriers. This evidence concerns the gene HLA-C and atypical teratoid rhabdoid tumor.